uk's cost agency rebuffs bristol arthritis drug
britain's healthcare cost watchdog nice has recommended against using bristol-myers squibb's rheumatoid arthritis drug orencia on the state health service as a second-line treatment.
http://feeds.reuters.com/~r/reuters/healthnews/~3/tk3q6vquxdk/us-uk-arthritis-drug-idustre72t5rs20110330
20019
30 Mar 2011 20:22:23
reuters
health